
Coronavirus JHM: nucleotide sequence of the mRNA that encodes nucleocapsid protein

M.A.Skinner and S.G.Siddell

Institute of Virology, University of Würzburg, 8700 Würzburg, FRG

Received 10 June 1983; Accepted 4 July 1983

ABSTRACT

A DNA copy of the mRNA that encodes the nucleocapsid protein of Mouse Hepatitis Virus JHM has been cloned into pAT153. The DNA copy specifically inhibited the synthesis in vitro of the nucleocapsid protein. The cDNA was subcloned into M13 vectors and the entire sequence, 1767 bases including a 15 base terminal poly (A) tract, has been determined by chain-terminator sequencing. The sequence contained an open-reading frame that could encode a basic protein of mol.wt. 49700. From the predicted sequence it was apparent that the nucleocapsid protein has 5 basic regions, two of which are located near the middle of the sequence, a serine-rich region was also located, a feature which may be of functional importance as the nucleocapsid protein is phosphorylated at serine residues. The carboxy terminus of the nucleocapsid protein was found to be acidic. The 5' non-coding sequence contained a triple repeat of the pentamer AATCT, a structural feature which may play a significant role during the production of subgenomic viral mRNAs.

INTRODUCTION

Coronaviruses are enveloped, positive-stranded RNA viruses which infect vertebrates and are responsible for diseases of clinical and economic importance, in particular respiratory and gastro-intestinal disorders¹. The most-studied member of the group is Murine Hepatitis Virus (MHV). Depending upon the age and genetic background of the host, different MHV strains display differences in virulence, pathogenicity and in organ and cell tropisms. They therefore provide useful models for a variety of disease processes. Of particular interest is the neurotropic MHV strain, JHM, which has the ability to induce acute and subacute disorders of the central nervous system in rodents and has been used as a model for virus-induced demyelination²⁻⁴.

The Mouse Hepatitis Virus (MHV) genome is a linear, unsegmented, infectious RNA which is about 18 kilobases long. MHV replicates in the cytoplasm of infected cells and the viral genetic information is expressed as one genome-sized and six subgenomic mRNAs. The largest (genome-sized) mRNA is termed mRNA 1 and the smaller mRNAs are numbered in order of decreasing size.

These mRNAs are synthesized in non-equimolar amounts but in constant proportions. For a review of coronavirus replication, see ref. 1. Analysis by RNase T₁ oligonucleotide fingerprinting and by hybridization to virus specific cDNA probes⁵⁻¹⁰, reveals that these mRNAs are 3'coterminal forming a "nested-set". Furthermore, analysis of RNase T₁ oligonucleotides from subgenomic mRNAs and from the equivalent regions of the genome suggests that the subgenomic mRNAs bear a leader sequence derived from the 5' end of the genome^{7,8}. The translation of MHV mRNAs in vivo, in cell-free systems or in oocytes¹¹⁻¹³, shows that each mRNA is translated independently to produce a single protein, the size of which corresponds to the coding capacity of the 5' sequences not found in the next smallest mRNA. The smallest and most abundant mRNA (mRNA7) encodes the virion nucleocapsid protein, a basic, phosphorylated polypeptide of 50-60000 mol.wt. The next most abundant RNA, mRNA6, encodes the virion matrix glycoprotein(s) (23000 to 25000 mol.wt.) and the third major intracellular RNA, mRNA3, encodes the virion peplomer glycoprotein(s) (90000 and 180000 mol.wt.). The remaining intracellular mRNAs, which are found in lesser amounts, are thought to encode viral non-structural proteins.

In the experiments described here, we have isolated DNA copies of MHV-JHM mRNA7 and obtained a complete sequence of the mRNA. This nucleotide sequence and the predicted sequence of the encoded protein can be compared with the equivalent sequences recently obtained for the hepatotropic MHV strain, A59¹⁴.

MATERIALS AND METHODS

Chemicals

Avian myeloblastosis virus reverse transcriptase was supplied by Life Sciences (St. Petersburg, Florida). Radiochemicals were supplied by Amersham Buchler (Braunschweig, F.R.G.). M13 pentadecamer sequencing and hybridization probes, oligo dT₁₂₋₁₈ and oligo dG₁₂₋₁₈ were obtained from PL Biochemicals (St. Goar, F.R.G.). Escherichia coli DNA polymerase I (large fragment), S1 nuclease and terminal deoxynucleotidyl transferase were obtained from Bethesda Research Laboratories (Neu-Isenburg, F.R.G.). New England Nuclear (Dreieich, F.R.G.) supplied T4 DNA ligase. Restriction enzymes were obtained from PL Biochemicals, Bethesda Research Laboratories and Boehringer Mannheim (Mannheim, F.R.G.).

Synthesis and Cloning of cDNA

Polyadenylated RNA was isolated from Sac(-) cells that had been infect-

ed with MHV-JHM, as previously described¹⁵. Double-stranded cDNA was prepared from 10 µg of polyadenylated RNA, using oligo dT and oligo dG to prime first and second strand synthesis, respectively, then oligo dC-tailed, double-stranded cDNA was annealed to PstI-cleaved, oligo dG-tailed pAT153, according to protocols described by Land et al¹⁶. *Escherichia coli* HB101 was transformed with the annealed plasmid/cDNA using the method of Dagert and Ehrlich¹⁷. Tetracycline-resistant, ampicillin-sensitive bacterial clones, from two independent cDNA cloning experiments, were screened for JHM-specific sequences by hybridization with a single-stranded cDNA probe, containing ³²P, that had been copied from genome RNA isolated from purified virions.

Characterization of cloned cDNA

The size of inserts in plasmids from strongly-hybridizing clones was determined by gel electrophoresis of DNA extracted by the method of Holmes and Quigley¹⁸. Plasmids containing the largest inserts were prepared from 1 litre cultures and were purified by equilibrium centrifugation in ethidium bromide/caesium chloride. Inserts were excised from the plasmids using PstI and were recovered from agarose gels by electroelution. The inserts were mapped by partial digestion with restriction enzymes of DNA that had been labelled using ³²P cordycepin triphosphate and terminal deoxynucleotidyl transferase.

Nucleotide sequencing

Fragments of two cDNA inserts were generated by a variety of restriction enzymes and cloned into the M13 vectors mp 8 and mp 9¹⁹. The fragments were sequenced using the chain terminator method of Sanger et al.²⁰. 77 % of the cDNA was sequenced on both strands, a further 14 % on different but overlapping fragments of the same strand and the remainder was sequenced at least twice. Towards the end of the sequencing project specific clones were identified by their hybridization to a panel of characterized M13 clones. M13 hybridization probes were prepared by the method of Hu and Messing²¹.

Translation in vitro, Hybrid-arrested translation and polyacrylamide gel electrophoresis

Polyadenylated RNA from cells infected with MHV-JHM was translated in a rabbit reticulocyte lysate as previously described¹⁵. Hybrid-arrested translation experiments, using purified cDNA insert and polyadenylated RNA from cells infected with MHV-JHM, were performed according to the method of Pater-son and Kuff²², using a rabbit reticulocyte lysate. Translation products were analysed on 15 % polyacrylamide gels²³.




Fig. 1

Hybrid-arrested translation of MHV-JHM mRNA7

Autoradiograph of the ^{35}S methionine-labelled products synthesized in a rabbit reticulocyte lysate and separated on a 15 % polyacrylamide-SDS gel. The samples translated were: (a) no added RNA, (b-f) 250 ng of polyadenylated, cytoplasmic RNA from cells infected with MHV-JHM, and either 500 ng of the insert DNA (c and d) or 1000 ng of the insert DNA (e and f). Samples (c) and (e) were in the hybrid conformation and samples (d) and (f) were heated to melt the hybrids. The major products of 60000 and 23000 mol.wt. have been identified as the nucleocapsid and matrix proteins respectively. Sample (m) contained ^{14}C -labelled molecular weight markers (CFA626, Amersham Buchler, Braunschweig, F.R.G.).

RESULTS

Identification of cDNA clones as copies of mRNA7

The largest JHM-specific cDNA clones from each of two cloning experiments (those within pMS38 and pSS38), were analyzed by digestion with restriction enzymes, showing that together they contained enough sequence to represent a full-length copy of mRNA7 (about 1800 bases²⁴). The insert in pSS38 was about 1700 base pairs and was therefore sufficient to account for most of mRNA7. The insert in pMS38 contained 830 base pairs. Mapping of both inserts, by partial digestion with restriction endonucleases, showed that the insert in pMS38 contained an extra 40 base pairs at one end.

Confirmation that the cDNA insert in pSS38 represented the body of mRNA7




Fig. 2

Diagram showing those restriction endonuclease sites, in the DNA copy of MHV-JHM mRNA 7, used for subcloning into M13 vectors. Solid arrows show the direction and extent of sequence obtained from each clone. Broken lines indicate the probable extent of each clone. Restriction endonuclease cleavage sites are denoted by the symbols: ● HaeIII, ▲ MspI, ◆ BalI, † AluI, ▾ Sau3a and ◇ PvuII. The box at the 3' terminus represents the poly(A) tract.

was obtained by hybrid-arrested translation (Fig. 1). When hybridized to cytoplasmic, polyadenylated RNA from cells infected with JHM, the insert specifically inhibited the translation of a 60000 mol.wt. polypeptide that has been previously identified as the intracellular precursor of the virion nucleocapsid protein produced from mRNA⁷¹⁵. Melting of the hybrids before translation restored the synthesis of nucleocapsid protein.

Nucleotide sequence of cloned cDNA

Fragments of both cDNA inserts were generated by various restriction enzymes (Fig. 2), cloned into M13 vectors and their sequences were determined. The combined sequence of 1767 base pairs (contained between the oligo dC/dG tails made during the process of cloning the cDNA) is presented in Fig. 3. A 5' non-coding sequence of 83 base pairs preceded the first AUG codon, which initiated an open reading frame (1365 bases long) with the potential to encode a basic polypeptide of 455 amino acids (49700 mol.wt.). The first putative termination codon in this reading frame was found at nucleotide 1449 and was followed by 301 base pairs of 3' non-coding sequence. A polyadenylate tract was found beginning at nucleotide 1753. The only other open-reading frame of greater than 100 bases was from nucleotides 361-771 (inclusive), which is potentially able to encode 137 amino acids. Within the 5' non-coding

TATAAGAGTGATTGGCGTCCGTACGTACCCTCTACTCTAAAACCTCTGTAGTTAAATCTAATCTAACTTAAAGG

(84) Met Ser Phe Val Pro Gly Gln Glu Asn Ala Gly Ser Arg Ser Ser Gly Asn Arg Ala Gly Asn Gly Ile Leu (25)
 ATG TCT TTT GTT CCT GGG CAA GAA AAT GCC GGT AGC AGA AGC TCC TCT GGA AAC CGC GCT GGT AAT GGA ATC CTC

(159) Lys Lys Thr Thr Trp Ala Asp Gln Thr Glu Arg Gly Leu Asn Asn Gln Asn Arg Gly Arg Lys Asn Gln Pro Lys (50)
 AAG AAG ACC ACT TGG GCT GAC CAA ACC GAG CGC GGG TTA AAT AAT CAA AAT AGA GGC AGA AAG AAT CAG CCC AAG

(234) Gln Thr Ala Thr Thr Gln Pro Asn Ser Gly Ser Val Val Pro His Tyr Ser Trp Phe Ser Gly Ile Thr Gln Phe (75)
 CAG ACT GCA AAT CAG CAA CCC AAT TCC GGG AGT GTG GTT CCC CAT TAC TCT TCC TTT

(309) Gln Lys Gly Lys Glu Phe Gln Phe Ala Gln Gly Gln Gly Val Pro Ile Ala Asn Gly Ile Pro Ala Ser Gln Gln (100)
 CAG AAG GGA AAA GAG TTT CAG TTT GCA CAA GGA CAA GGA GTG CCT ATT GCC AAT GGA ATC CCA GCT TCA CAG CAA

(384) Lys Gly Tyr Trp Tyr Arg His Asn Arg Arg Ser Phe Lys Thr Pro Asp Gly Gln Gln Lys Gln Leu Leu Pro Arg (125)
 AAG GGA TAT TGG TAC AGA CAC AAC CGA CGT TCC TTT AAA ACA CCA GAT GGC CAG CAG AAG CAG CTA CTG CCC AGA

(459) Trp Tyr Phe Tyr Tyr Leu Gly Thr Gly Pro Tyr Ala Gly Ala Glu Tyr Gly Asp Asp Ile Glu Gly Val Val Trp (150)
 TGG TAT TTT TAC TAT CTT GGA ACA GGG CCC TAT GCT GGC GCA GAG TAT GGC GAC GAT ATC GAA GGA GTT GTC TGG

(534) Val Ala Ser Gln Gln Ala Glu Thr Arg Thr Ser Ala Asp Ile Val Glu Arg Asp Pro Ser Ser His Glu Ala Ile (175)
 GTC GCA AGC CAA CAG GCC GAG ACC TCC GGC GAT ATT GTT AAA AGG GGC CCA AGC AGC TCC AAC CAG CGC CAG CCT

(609) Pro Thr Arg Phe Ala Pro Gly Thr Val Leu Pro Gln Gly Phe Tyr Val Glu Gly Ser Gly Arg Ser Ala Pro Ala (200)
 CCT ACT AGG TTT GCG CCC GGT ACG GTA TTG CCT CAA GGT TTT TAT GTT GAA GGC TCA GGA AGG TCT GCA CCT GCT

(684) Ser Arg Ser Gly Ser Arg Pro Gln Ser Arg Gly Pro Asn Asn Arg Ala Arg Ser Ser Ser Asn Gln Arg Gln Pro (225)
 AGT CGA TCT GGT TCG CGG CCA CAA TCC CGT GGG CCA AAT AAT CCG GCT AGA AGC AGT TCC AAC CAG CGC CAG CCT

(759) Ala Ser Thr Val Lys Pro Asp Met Ala Glu Glu Ile Ala Ala Leu Val Leu Ala Lys Leu Gly Lys Asp Ala Gly (250)
 GCC TCT ACT GTA AAA CCT GAT ATG GCC GAA GAA ATT GCT GCT CTT GTT TTG GCT AAG CTC GGT AAA GAT GCC GGC

(834) Gln Pro Lys Gln Val Thr Lys Gln Ser Ala Lys Glu Val Arg Gln Lys Ile Leu Asn Lys Pro Arg Gln Lys Arg (275)
 CAG CCT AAG CAA GTA ACA AAG CAA AGT GCC AAA GAA GTC AGG CAG AAA ATT TTA AAC AAG CCT CGT CAA AAG AGG

(909) Thr Pro Asn Lys Gln Cys Pro Val Gln Gln Cys Phe Gly Lys Arg Gly Pro Asn Gln Asn Phe Gly Gln Pro Glu (300)
 ACT CCA AAC AAG CAG TGC CCA GTG CAG CAG TGT TTT GGA AAG AGA GGC CCC AAT CAG AAT TTT GGA GGC CCT GAA

(984) Met Leu Lys Leu Gly Thr Ser Asp Pro Gln Phe Pro Ile Leu Ala Glu Leu Ala Pro Thr Ala Gly Ala Phe Phe (325)
 ATG TTA AAA CTT GGA ACT AGT GAT CCA CAG TTC CCC ATT CTT GCA GAG TTG GCC CCA ACA GCT GGT GCC TTC TTC

(1059) Phe Gly Ser Lys Leu Glu Leu Val Lys Lys Asn Ser Gly Gly Ala Asp Gly Pro Thr Lys Asp Val Tyr Glu Leu (350)
 TTT GGA TCT AAA TTA GAA TTG GTC AAA AAG AAC TCT GGT GGT GCT GAT GGA CCC ACC AAA GAT GTG TAT GAG CTG

(1134) Gln Tyr Ser Gly Ala Val Arg Phe Asp Ser Thr Leu Pro Gly Phe Glu Thr Ile Met Lys Val Leu Asn Glu Asn (375)
 CAA TAT TCA GGT GCA GTT AGA TTT GAT AGT ACT CTA CCT GGT TTT GAG ACT ATC ATG AAA GTG TTG AAT GAG AAT

(1209) Leu Asn Ala Tyr Gln Asn Gln Asp Gly Gly Ala Asp Val Val Ser Pro Lys Pro Gln Arg Lys Arg Gly Thr Lys (400)
 TTG AAT GCC TAC CAG AAT CAA GAT GGT GGT GCA GAT GTA GTG ACC CTT AAG CCT CAG AGA AAG AGA GGG ACA AAG

(1284) Gln Lys Ala Gln Lys Asp Glu Val Asp Asn Val Ser Val Ala Lys Pro Lys Ser Ser Val Gln Arg Asn Val Ser (425)
 CAA AAG GCT CAG AAA GAT GAA GTA GAT AAT GTA AGC GTT GCA AAG CCC AAA AGC TCT GTG CAG CGA AAT GTA AGT

(1359) Arg Glu Leu Thr Pro Glu Asp Arg Ser Leu Leu Ala Gln Ile Leu Asp Asp Gly Val Val Pro Asp Gly Leu Glu (450)
 AGA GAG TTA ACC CCT GAG GAT CGC AGC CTT CTG GCT CAG ATC CTA GAT GAT GGC GTA GTG CCA GAT GGG TTA GAA

(1434) Asp Asp Ser Asn Val
 GAT GAC TCT AAT GTG TAAAGAGAATGAATCCTATGTCCGCACCTCGGTGGTAACCCCTCCGCGAAGATGCGGATAGGACACTCTCTATCAGAAT

(1528) GGATGTCTTGCTGCATAACAGATAGAGAAGGTTGTGGCAGACCCGTATCAATTAGTTGAAAGAGATTCGAAATAGAGAATGTGTGAGAGAAGTTAG

(1627) CAAGGTCCTACGCTAACCTAAGAACGGCAGATAGGCGCCCCCTGGGAAGAGCTCACATCAGGGTACTATTCCTGCAATGCCCTAGTAAATGAATGAAG

(1726) TTGATCATGGCCAATTGGGAAGAATCACAAAAAATAAAAAAAAAA

Fig. 3 Complete nucleotide sequence of the DNA copy of MHV-JHM mRNA7 (1767 nucleotides), including a 15 base long, terminal poly (A) tract. The predicted sequence of the encoded protein is also depicted.

sequence, two large, RNase T₁-resistant oligonucleotides were found (at positions 26-50 and 54-82), the compositions of which were very similar to those of the MHV-A59 oligonucleotides 10 and 19⁸, respectively. Strikingly, the larger oligonucleotide contained a triple repeat of the pentamer AATCT and this sequence was found within both, independently generated clones.

DISCUSSION

Analysis of the sequence of MHV genome RNA and subgenomic mRNAs is a way of predicting the primary structure of encoded polypeptides and, at the same time, identifying non-coding sequences which may be relevant to the regulation of the viral genes. A comparative analysis of the sequences of different MHV strains, or mutants with altered phenotypes, will also be needed as a basis for further studies on MHV replication and pathogenicity.

Three criteria define the cloned sequences we have described here as representing the MHV-JHM nucleocapsid gene. Firstly, the 3' terminal location of this sequence on the genome (unpublished data) is consistent with the known gene order of MHV-JHM¹¹. Secondly, the cloned DNA has the ability to specifically arrest the translation *in vitro* of mRNA⁷ and, thirdly, the characteristics of the predicted polypeptide as a basic protein of 49700 mol.wt. are consistent with the electrophoretic properties of the nucleocapsid protein in two-dimensional, non-equilibrium, pH gradient, gel electrophoresis²⁵. We believe that the cDNA sequence represents a complete copy of mRNA⁷ because it extends from a polyadenylate tract to a 5' terminal sequence UAUAG, which is very similar to the cap-NUAAG sequence found by direct sequencing at the 5' terminus of mRNAs of the related MHV-A59⁸.

Examination of the sequence of MHV-JHM mRNA⁷ reveals several interesting features. The presence of the two large RNase T₁-resistant oligonucleotides (with similar base compositions to oligonucleotides 10 and 19 of A59⁸) within the 5' non-coding sequence supports the proposal that MHV subgenomic mRNAs contain a leader sequence^{7,8}. The A59 oligonucleotide 10 (equivalent to the JHM oligonucleotide at position 26 - 50) is found in all subgenomic mRNAs and in genomic RNA. It is not, however, found in 3' terminal fragments of the genome corresponding to mRNA⁷ and so must be nearer the 5' end of the genome. A59 oligonucleotide 19 (equivalent to the JHM oligonucleotide at position 54 - 82) is found only in mRNA⁷, but not in the equivalent region of the genome, and related oligonucleotides are found in other mRNAs. It has therefore been suggested that oligonucleotide 10 is contained within a leader sequence⁷ derived from the 5' end of the genome and that oligonucleotide 19 is formed by fusion of the leader to the body of mRNA^{7,8}. The relative positions of the equivalent JHM oligonucleotides are consistent with this proposal. It is interesting to note that the JHM equivalent of oligonucleotide 19 contained the triple repeat of the pentamer AATCT. It is likely that such a striking feature has a significant functional role in the production of subgenomic mRNAs. MHV is known to replicate in the absence of

the host cell nucleus^{27,28}. It has also been shown that the target size for the UV inactivation of the synthesis of each MHV mRNA is identical to the physical size of the mRNA²⁹. Thus the mRNAs cannot be produced by splicing of larger precursors. It has been suggested⁷ that the mRNAs could be produced by extension of a virus-encoded RNA primer or by a previously undescribed, unusually-specific polymerase jumping mechanism.

From the sequence alone, it is difficult to speculate about the importance of specific features of the nucleocapsid protein structure, at least until more is known about the interactions between nucleocapsid protein and genome RNA and between the ribonucleoprotein complex and other virion proteins. Particularly intriguing is the specific interaction of nucleocapsid protein with genome RNA but not with subgenomic mRNAs. The MHV-JHM nucleocapsid protein does not contain the clusters of lysine residues seen in the N-terminal portion of the capsid protein of Semliki Forest Virus³⁰ so, in this respect, it is similar to the nucleocapsid protein of influenza virus³¹. Some regions enriched in basic amino acids are however apparent (e.g. arg-43 to lys-50, lys-101 to lys-113, arg-196 to lys-230, arg-264 to arg-290 and lys-392 to lys-405) and, as in the nucleocapsid protein of Semliki Forest Virus, the carboxy terminus is acidic. The region ser-194 to ser-220 contains 9 serine residues, or 24 % of the total serine content within 6 % of the coding sequence. Moreover, this is a basic region of the protein. Another 4 serines are found in the five residues from ser-12 to ser-16. This clustering of serine residues may be significant in view of the fact that JHM nucleocapsid protein is phosphorylated specifically at serine residues³².

The sequence of MHV-JHM mRNA⁷ can also be compared with the recently published sequence of the nucleocapsid gene of MHV-A59¹⁴. The major differences between the JHM coding sequence reported here and the sequence reported for MHV-A59¹⁴ are that the JHM sequence contains an additional base (nucleotide 408) and lacks a base (after nucleotide 725). However, it is now clear (J. Armstrong, personal communication) that the A59 sequence should be identical to the JHM sequence at these positions. Therefore, the two sequences are very similar, with a 94 % overall homology within the coding sequence. This finding is in accord with the degree of homology based on hybridization kinetics of cDNA, copied from MHV-A59 mRNA⁷, with mRNA from cells infected with MHV-JHM²⁸. Although the sequence homology is so high overall, it is not constant throughout the length of the coding sequence. Between nucleotides 497 and 569 the homology falls to 63 % and in a sequence of 23 bases (nucleotides 1271-1293) near the 3' end of the coding sequence,

only 9 bases are common to both strains. Also, an extra glutamine codon is found in the JHM sequence at nucleotide 1227.

The non-coding regions of mRNA7 from MHV-JHM and those reported for MHV-A59¹⁴ may also be compared. The 5' non-coding sequences are identical for the 17 nucleotides immediately before the AUG codon but the rest of the JHM 5' non-coding sequence is different from the sequence reported for A59¹⁴. More recent studies on the sequence of A59 subgenomic messengers (J. Armstrong, personal communication) have shown that the reported 5' non-coding sequence¹⁴ is not derived from mRNA7 and therefore further comparison cannot be made. When the 3' non-coding sequences are compared, they are found to be highly conserved (98 % homology). We believe that this conservation of sequence at the termini of MHV RNA is significant and is most likely related to the interaction of these molecules with RNA polymerase during the synthesis of negative stranded template as well as during the production of subgenomic mRNAs and the replication of genome RNA.

In conclusion, this comparison reveals that, as might have been expected, the sequence encoding the nucleocapsid protein of MHV is relatively conserved, even between strains of MHV that show differences in pathogenicity. Our immediate aim is to determine the level of sequence homology, between the same strains, for genes more directly involved in the interaction between virus and the host cells.

ACKNOWLEDGEMENTS

We thank Helga Kriesinger for typing the manuscript and Dr. M. Carter for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft.

REFERENCES

1. Siddell, S., Wege, H. and ter Meulen, V. (1983). *J. Gen. Virol.* **64**, 761-776.
2. Knobler, R.L., Lampert, P.W. and Oldstone, M.B.A. (1982). *Nature* **298**, 279-280.
3. Wege, H., Koga, M., Watanabe, R., Nagashima, K. and ter Meulen, V. (1983). *Infect. Immun.* **39**, 1316-1324.
4. Dubois-Dalcq, M.E., Dötter, E.W., Haspel, M.V. and Holmes, K.V. (1982). *Virology* **119**, 317-331.
5. Leibowitz, J.L., Wilhelmson, K.C. and Bond, C.W. (1981). *Virology* **114**, 39-51.
6. Lai, M.M.C., Brayton, P.R., Armen, R.C., Patton, C.D., Pugh, C. and Stohlman, S. (1981). *J. Virol.* **39**, 823-834.
7. Spaan, W.J.M., Rottier, P.J.M., Horzinek, M.C. and van der Zeijst, B.A.M. (1982). *J. Virol.* **42**, 432-439.

8. Lai, M.M.C., Patton, C.D. and Stohman, S.A. (1982). *J. Virol.* 41, 557-565.
9. Cheley, S., Anderson, R., Cupples, M.J., Lee Chan, E.C. and Morris, V.L. (1981). *Virology* 112, 596-604.
10. Weiss, S.R. and Leibowitz, J.L. (1983). *J. Gen. Virol.* 64, 127-133.
11. Siddell, S.G. (1983). *J. Gen. Virol.* 64, 113-125.
12. Rottier, P.J.M., Spaan, W.J.M., Horzinek, M. and van der Zeijst, B.A.M. (1981). *J. Virol.* 38, 20-26.
13. Leibowitz, J.L., Weiss, S.R., Paavola, E. and Bon, C.W. (1982). *J. Virol.* 43, 905-913.
14. Armstrong, J.A., Smeekens, S. and Rottier, P. (1983). *Nucl. Ac. Res.* 11, 883-891.
15. Siddell, S.G., Wege, H., Barthel, A. and ter Meulen, V. (1980). *J. Virol.* 33, 10-17.
16. Land, H., Grez, M., Hauser, H., Lindenmaier, W. and Schütz, G. (1983). In *Methods in Enzymology*, eds. Wu, R., Grossman, L. and Moldave, K. (Academic Press, New York), Vol. 100, in press.
17. Dagert, M. and Ehrlich, S.D. (1979). *Gene* 6, 23-28.
18. Holmes, D.S. and Quigley, M. (1981). *Anal. Biochem.* 114, 193-197.
19. Messing, J. and Vierira, J. (1982). *Gene* 19, 269-276.
20. Sanger, F., Nicklen, S. and Coulson, A.R. (1977). *Proc. Natl. Acad. Sci. USA* 74, 5463-5467.
21. Hu, N. and Messing, J. (1982). *Gene* 17, 271-277.
22. Paterson, B.M., Roberts, B.E. and Kuff, E.L. (1977). *Proc. Nat. Acad. Sci. USA* 74, 4370-4374.
23. Laemli, U.K. (1970). *Nature (London)* 227, 680-685.
24. Wege, H., Siddell, S., Sturm, M. and ter Meulen, V. (1981). *J. Gen. Virol.* 54, 213-217.
25. Siddell, S., Wege, H., Barthel, A. and ter Meulen, V. (1981). *J. Gen. Virol.* 53, 145-155.
26. Cheley, S., Morris, V.L., Cupples, M.J. and Anderson, R. (1981). *Virology* 115, 310-321.
27. Brayton, P.R., Ganges, R.G. and Stohman, S.A. (1981). *J. Gen. Virol.* 56, 457-460.
28. Wilhelmson, K.C., Leibowitz, J.L., Bond, C.W. and Robb J.A. (1981). *Virology* 110, 225-230.
29. Jacobs, L., Spaan, W.J.M., Horzinek, M.C. and van der Zeijst, B.A.M. (1981). *J. Virol.* 39, 401-406.
30. Garoff, H., Frischauf, A., Simons, K., Lehrach, H. and Delius, H. (1980). *Proc. Natl. Acad. Sci. USA* 77, 6376-6380.
31. Winter, G. and Fields, S. (1981). *Virology* 114, 423-428.
32. Siddell, S.G., Barthel, A. and ter Meulen, V. (1981). *J. Gen. Virol.* 52, 235-243.